6.38
3.77%
-0.25
Dopo l'orario di chiusura:
6.36
-0.02
-0.31%
Bioventus Inc Borsa (BVS) Ultime notizie
Bioventus Inc - (BVS) Price Target Increased by 40.00% to 3.57 - MSN
MSN
Bioventus (NYSE:BVS) Shares Up 4.4% - MarketBeat
MarketBeat
Here's Why You Should Retain Centene (CNC) Stock for Now
Zacks Investment Research
Bioventus (NYSE:BVS) Releases FY 2024 Earnings Guidance - MarketBeat
MarketBeat
Bioventus (NYSE:BVS) Price Target Increased to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
MarketBeat
Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant Growth and Improved ... - GuruFocus.com
GuruFocus.com
Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Bioventus (NYSE:BVS) Price Target Increased to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
MarketBeat
Bioventus gains after raising annual sales, profit forecasts - XM
XM
Bioventus Reports First Quarter Financial Results - 07.05.2024 - wallstreet:online
wallstreet:online
Bioventus stock target increased on Q1 performance By Investing.com - Investing.com
Investing.com
Bioventus (BVS) to Release Earnings on Tuesday - Defense World
Defense World
Bone and Joint Regenerative Medicines Market 2024 Segment Analysis | Anika Therapeutics Inc., Arthrex Inc., Baxter ... - Motions Online
Motions Online
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
GlobeNewswire Inc.
BVS Stock Quote Price and Forecast - CNN
CNN
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga
Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Bioventus, Inc. on the Brink: Navigating Financial Control Challenges and Investor Confidence - TipRanks.com - TipRanks
TipRanks
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday
Benzinga
Bioventus Surges with 7.6% Q4 Revenue Growth to $135.4M, Outstripping Expectations - The Tokenist
The Tokenist
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders ... - GlobeNewswire
GlobeNewswire
Bioventus: Bullish On Path To Profitability (NASDAQ:BVS) - Seeking Alpha
Seeking Alpha
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
GlobeNewswire Inc.
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
GlobeNewswire Inc.
Durham-based Bioventus names veteran life science exec as CEO - WRAL TechWire
WRAL TechWire
Bioventus Names Robert Claypoole as President and Chief Executive Officer
GlobeNewswire Inc.
MedTech Bioventus' Stabilization Sparks Analyst Confidence, Earns Upgrade And Price Target Boost
Benzinga
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee ... - OrthoSpineNews
OrthoSpineNews
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
GlobeNewswire Inc.
Smith+Nephew steps up with $330M acquisition of Cartiheal - BioWorld Online
BioWorld Online
Smith+Nephew swoops in with $330M offer for CartiHeal after Bioventus bows out - Fierce Biotech
Fierce Biotech
Bioventus Stock: Improving Outlook Keeps It Interesting (NASDAQ:BVS) - Seeking Alpha
Seeking Alpha
Juniper Investment Company, LLC Increases Stake in Bioventus Inc - Yahoo Finance
Yahoo Finance
Reed Smith represents Bioventus in sale of its wound business to LifeNet Health | Neuigkeiten - Reed Smith LLP
Reed Smith LLP
Over $1M Bet On Bioventus? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Markets Insider
Markets Insider
Bioventus completes wound business divestiture - Mass Device
Mass Device
LifeNet Health acquires best-in-class wound care portfolio - PR Newswire
PR Newswire
Chancery Trims Suit Over $110M Bioness-Bioventus Deal - Law360
Law360
Bioventus unseats CEO as CartiHeal deal falls apart - Fierce Biotech
Fierce Biotech
Bioventus Appoints Anthony Bihl As Interim CEO - citybiz
citybiz
Is Bioventus Backing Out of CartiHeal Deal? - https://ryortho.com/
https://ryortho.com/
Smith & Nephew profits shrink amid major fall in Bioventus shareholding - This is Money
This is Money
Pomerantz Law Firm Announces the Filing of a Class Action Against Bioventus Inc. and Certain Officers and Directors ... - PR Newswire
PR Newswire
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses - GlobeNewswire
GlobeNewswire
Why Shares of Bioventus Fell 14% on Wednesday - The Motley Fool
The Motley Fool
Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight - GlobeNewswire
GlobeNewswire
Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript - The Motley Fool
The Motley Fool
Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan - Fierce Biotech
Fierce Biotech
Capitalizzazione:
|
Volume (24 ore):